GI Stool Testing Market Report 2026

The gi stool testing market size has grown strongly in recent years. It will grow from $1.41 billion in 2025 to $1.51 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to growth in gastrointestinal disorders, advances in diagnostic laboratories, early microbiology testing, rising colorectal cancer screening, healthcare awareness.

The gi stool testing market size is expected to see strong growth in the next few years. It will grow to $1.99 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to expansion of personalized gut health testing, growth of home diagnostics, integration of ai-based analysis, preventive healthcare adoption, rising digestive health awareness. Major trends in the forecast period include growing demand for non-invasive diagnostics, rising adoption of microbiome-based testing, increased use of molecular diagnostic methods, expansion of home-based stool testing kits, improved early detection of gi disorders.

The rising prevalence of gastrointestinal disorders is expected to drive the growth of the GI stool testing market in the coming years. Gastrointestinal disorders encompass conditions affecting the digestive system, including the stomach, intestines, and associated organs, causing symptoms like nausea, diarrhea, constipation, and abdominal pain. This increase is largely due to poor dietary habits, such as high consumption of processed foods, excessive sugar intake, and low-fiber diets, which disrupt gut microbiota, impair digestive health, and contribute to conditions like acid reflux, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD). GI stool testing plays a critical role in diagnosing gastrointestinal disorders by detecting infections, inflammation, or digestive imbalances. It identifies pathogens (bacteria, viruses, parasites), markers of gut inflammation, and enzyme deficiencies, enabling precise diagnosis and targeted treatment. For instance, in September 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that between 2024 and 2025, NoroSTAT-participating states recorded 1,676 norovirus outbreaks, a notable increase from 729 outbreaks during the same period in the previous season. Therefore, the rising prevalence of gastrointestinal disorders is driving the GI stool testing market.

The increasing expansion of healthcare infrastructure is expected to propel the growth of the GI stool testing market going forward. Healthcare infrastructure encompasses the physical, technological, and organizational resources necessary to deliver medical services, including hospitals, clinics, equipment, and digital health systems. Growth in healthcare infrastructure is fueled by a rising population and aging demographics, as longer life expectancy and higher disease prevalence increase the demand for hospitals, clinics, and advanced medical facilities to ensure access to care and improved patient outcomes. Expanded healthcare infrastructure enhances the availability and precision of GI stool testing, as better laboratory facilities, advanced diagnostic technologies, and well-trained healthcare professionals enable faster, more accurate detection of gastrointestinal disorders, supporting timely treatment and improved patient care. For instance, in November 2024, The Health Foundation, a UK-based independent charity, reported that Department of Health and Social Care (DHSC) spending is projected to increase from $227.6 billion in 2023/24 to $238.6 billion in 2024/25 and $250.6 billion in 2025/26, reflecting an average annual real-term growth of 3.3%. Therefore, the growing healthcare infrastructure is driving the GI stool testing market.

Major companies in the GI stool testing market are focusing on advanced diagnostic technologies, such as comprehensive testing solutions, to enhance accuracy, speed, and early detection of diseases. Comprehensive diagnostic tests evaluate multiple health parameters simultaneously, offering a complete assessment of a condition. For instance, in November 2024, EmeritusDX, a US-based diagnostics company, launched GI Detect, a comprehensive diagnostic test designed to help healthcare providers identify gastrointestinal disorders. This innovative test uses a single stool swab to detect 26 bacteria, viruses, and parasites linked to digestive system disruptions. With a 24-hour turnaround, GI Detect enables rapid, informed clinical decision-making. In addition to broad pathogen detection, the test screens for Helicobacter pylori and its virulence factors VacA, cagA, and babA, as well as common gastrointestinal parasites such as Cryptosporidium, Entamoeba histolytica, and Giardia lamblia. This comprehensive approach ensures timely and accurate diagnosis of gastrointestinal infections.

Major companies operating in the gi stool testing market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Hologic Inc., Biomerieux SA, Bio‑Rad Laboratories Inc., Meridian BioScience Inc., Diasorin SPA, ELITechGroup, Genova Diagnostics Inc., US BioTek Laboratories LLC, Doctor's Data Inc., Diagnostic Solutions Laboratory LLC, Functional Medical Institute Pvt. Ltd., Walk‑In Lab LLC, ScheBo Biotech AG, Qiagen NV, Roche Diagnostics, Siemens Healthineers, QuidelOrtho Corporation, Biohit Oyj, Exact Sciences Corporation.

North America was the largest region in the GI stool testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gi stool testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gi stool testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gi stool testing market by increasing costs of imported diagnostic kits, reagents, and laboratory equipment. Diagnostic laboratories and hospitals are most affected due to reliance on imported testing technologies. These tariffs raise testing costs by increasing per-test consumable expenses and equipment servicing costs, potentially limiting routine gastrointestinal screening. However, they support domestic diagnostic kit manufacturing, improving local availability of stool testing solutions.

The gi stool testing market research report is one of a series of new reports that provides gi stool testing market statistics, including gi stool testing industry global market size, regional shares, competitors with a gi stool testing market share, detailed gi stool testing market segments, market trends and opportunities, and any further data you may need to thrive in the gi stool testing industry. This gi stool testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastrointestinal (GI) stool testing involves analyzing stool samples to evaluate gastrointestinal health and detect infections, digestive disorders, and inflammatory conditions. This testing helps identify microbial imbalances, deficiencies in digestive enzymes, and markers of gut inflammation. As a non-invasive diagnostic approach, it supports early disease detection and personalized treatment planning.

The main types of GI stool testing include immunoassay tests, molecular diagnostic tests, chromatography-based tests, microbiological culture tests, and enzyme-linked immunosorbent assay (ELISA). An immunoassay test is a diagnostic method that uses antibodies to detect specific antigens or proteins in stool samples. It can utilize both fecal and serum samples and involves various equipment, such as automated analyzers, benchtop instruments, and portable devices. These tests are applied for diagnosing gastrointestinal disorders, screening for colorectal cancer, monitoring inflammatory bowel disease (IBD), detecting gastrointestinal infections, and assessing digestive health. They are used by a range of end users, including hospitals, diagnostic centers and laboratories, academic institutions, research organizations, home care providers, and others.

The GI stool testing market consists of revenues earned by entities by providing services such as microbiome analysis, pathogen detection, colorectal cancer screening, digestive health assessment, and inflammatory marker testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The GI stool testing market also includes sales of stool test kits, reagent solutions, sample collection devices, diagnostic analyzers, and laboratory consumables. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.